Nextcure and nordic bioscience publish review article on the regulation of tumor immunity by tumor collagen

Beltsville, md., sept. 07, 2023 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a review article in the online journal frontiers in immunology, highlighting the need for targeting tumor collagen in the extracellular matrix (ecm) in the tumor microenvironment to enhance anti-tumor immunity.
NXTC Ratings Summary
NXTC Quant Ranking